NeoImmuneTech, Inc. announced it will present first data from the combination of its main asset, NT-I7, with the chimeric antigen receptor T-cell tisagenlecleucel, at the American Society of Hematology annual meeting, to be held in New Orleans, Louisiana, December 10-13, 2022.
Early preliminary results show NT-I7 treatment led to a sustained increase in absolute lymphocyte counts (ALC) and increased CAR-T cell absolute numbers in the peripheral blood
ROCKVILLE, Md., Nov. 4, 2022 /PRNewswire/ -- NeoImmuneTech, Inc. (NIT or “NeoImmuneTech”), a clinical-stage T cell-focused biopharmaceutical company, today announced it will present first data from the combination of its main asset, NT-I7 (efineptakin alfa), with the chimeric antigen receptor T-cell (CAR-T) tisagenlecleucel, at the American Society of Hematology (ASH) annual meeting, to be held in New Orleans, Louisiana, December 10-13, 2022.
The NIT-112 phase 1b study is the first and only clinical trial that aims to evaluate the safety, tolerability, and preliminary anti-tumor activity of a long-acting human IL-7, NT-I7 (efineptakin alfa), after treatment with tisagenlecleucel (Kymriah®) in patients with relapsed/refractory large B-cell Lymphoma (r/r LBCL).
Tisagenlecleucel (Kymriah®), a CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy, has become standard of care for patients with r/r LBCL. The successful expansion and persistence of CAR-T cells strongly predicts response to this therapy. The scientific hypothesis is that the combination may increase expansion and persistence of CAR-T, increasing tumor response rate and improving clinical outcomes without safety concerns.
As of 30 May, 2022, only the first three dose escalation groups out of seven dose levels (DL1-7: 60, 120, 240, 360, 480, 600, and 720 μg/kg of NT-I7) had completed recruitment. No serious adverse events were observed. All patients experienced treatment-emergent adverse events, most of which were mild. Despite the limited number of patients currently enrolled in the lowest NT-I7 dose levels (DL1-3), and CAR-T levels being near the limit of assay detection, a single dose of NT-I7 at the CAR-T contraction phase (day 21) was able to increase both the absolute lymphocyte count (ALC) and the CAR-T absolute numbers.
Dr Se Hwan Yang, Ph.D., President and Chief Executive Officer of NeoImmuneTech, Inc. said: “The early results of the Phase 1b study NIT-112 are promising and may have strong clinical implications. We feel encouraged to further investigate NT-I7 in combination with tisagenlecleucel as a potential efficacious addition to CAR-T standard of care in relapsed/refractory large B-cell lymphoma”.
NIT presentation at the 2022 ASH Annual Meeting:
| Primary Author | Abstract Title | Presentation Details |
| Ghobadi, A
| A Phase 1b Dose Expansion Study Evaluating Safety, Preliminary Anti-Tumor Activity, and Accelerated T Cell Reconstitution with NT-I7 (Efineptakin Alfa), a Long-Acting Human IL-7, Administered Following tisagenlecleucel in Subjects with Relapsed/Refractory Large B- Cell Lymphoma |
|
About NT-I7 (efineptakin alfa) (rhIL-7-hyFc)
NT-I7 (efineptakin alfa) is the only clinical-stage long-acting human IL-7 and is being developed in oncologic and immunologic indications, where T cell amplification and increased functionality may provide clinical benefit. IL-7 is a fundamental cytokine for naïve and memory T cell development and sustaining immune response to chronic antigens (as in cancer) or foreign antigens (as in infectious diseases). NT-I7 exhibits favorable PK/PD and safety profiles, making it an ideal combination partner. NT-I7 is being studied in multiple clinical trials in solid tumors and as vaccine adjuvant. Studies are being planned for testing in hematologic malignancies, additional solid tumors and other immunology-focused indications.
About NeoImmuneTech, Inc.
NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company dedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious diseases. NIT is led by the scientific founder and inventor of NT-I7 (efineptakin alfa) and has a strong executive team with rich industry experience. NIT is expanding rapidly in personnel and operations, as well as partnering with industry and academic leaders to investigate NT-I7 as monotherapy and in combination with various immunotherapeutics. For more information, please visit www.neoimmunetech.com.
Forward-looking Statements
The statements contained herein may contain certain forward-looking statements relating to NeoImmuneTech, Inc. (the “Company”) that are based on its beliefs and expectations about the future. These forward-looking statements are based on a number of assumptions about the future, some of which are beyond the Company’s control and are not a guarantee of future performance or developments. Such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company does not undertake any obligation to update any forward-looking statements to reflect events that occur or circumstances that arise after the date of these documents. Accordingly, you should not place reliance on any forward-looking information or statements contained herein.
Some of the data contained in these documents were obtained from various external sources, and the Company has not independently verified such data. Accordingly, the Company makes no representations as to the accuracy or completeness of the data, and such data involves risks and uncertainties and is subject to change based on various factors.
View original content:https://www.prnewswire.com/news-releases/neoimmunetech-to-present-first-data-on-nt-i7-efineptakin-alfa-in-combination-with-car-t-tisagenlecleucel-at-2022-ash-annual-meeting-301668788.html
SOURCE The NeoImmuneTech, Inc
